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Available online 15 June 2016Mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia are preceded by a phase of disease,
referred to as ‘preclinical AD’, during which cognitively normal individuals have evidence of AD pathology in
the absence of clinical impairment. This study examined whether a magnetic resonance imaging (MRI) measure
of cortical thickness in brain regions, collectively known as ‘AD vulnerable’ regions, predicted the time to onset of
clinical symptoms associated with MCI and whether cortical thickness was similarly predictive of clinical
symptom onset within 7 years post baseline versus progression at a later point in time. These analyses included
240 participants from the BIOCARD study, a cohort of longitudinally followed individuals who were cognitively
normal at the time of their MRI (mean age = 56 years). Participants have been followed for up to 18 years
(M follow-up = 11.8 years) and 50 participants with MRIs at baseline have developed MCI or dementia over
time (mean time to clinical symptom onset = 7 years). Cortical thickness in AD vulnerable regions was based
on themean thickness of eight cortical regions. Using Cox regression models, we found that lower mean cortical
thickness was associated with an increased risk of progression from normal cognition to clinical symptom onset
within 7 years of baseline (p=0.03), but not with progression N7 years from baseline (p=0.30). Lower cortical
thickness was also associated with higher levels of phosphorylated tau, measured in cerebrospinal ﬂuid at
baseline. These results suggest that cortical thinning in AD vulnerable regions is detectable in cognitively normal
individuals several years prior to the onset of clinical symptoms that are a harbinger of a diagnosis of MCI, and
that the changes are more likely to be evident in the years proximal to clinical symptom onset, consistent with
hypothetical AD biomarker models.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Evidence indicates that the neuropathological changes underlying
Alzheimer's disease (AD) begin many years before the manifestation
of clinical symptoms (Sperling et al., 2011). A number of magnetic
resonance imaging (MRI) studies demonstrate alterations in selected
regions within the medial temporal lobe (MTL) that are thought to be
an indirect reﬂection of neuronal injury during this preclinical phase
of AD. For example, there is evidence that measures of the volume
and thickness of MTL regions, such as the entorhinal cortex and hippo-
campus, are associated with the time to diagnosis of mild cognitive
impairment (MCI) or time to onset of clinical symptoms associatedscience, 1620 McElderry Street,
. This is an open access article underwith MCI (e.g., Csernansky et al., 2005; Soldan et al., 2015). A greater
rate of atrophy in MTL regions has also been demonstrated among
cognitively normal individuals who subsequently progress to MCI
(e.g., Jack et al., 2004; Miller et al., 2013; Pacheco et al., 2015) compared
to individuals who remain cognitively normal.
It is currently hypothesized that structural brain changes are also
evident outside of the MTL during the preclinical phase of AD, though
most of this work is based on cross-sectional or short-term longitudinal
studies. Several groups have identiﬁed ‘AD vulnerable’ or ‘AD signature’
regions comprised of cortical areas thought to be particularly sensitive
to the effects of early AD pathology (e.g., Dickerson et al., 2009;
Sabuncu et al., 2011;Wang et al., 2015). Although the regions identiﬁed
as ‘AD vulnerable’ or ‘AD signature’ have differed across studies, they
predominantly include parts of inferior and anterior temporal lobe,
inferior and superior parietal lobe, and posterior cingulate cortex. For
example, a larger percentage of cognitively normal individuals withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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decline over a three-year follow-up (Dickerson and Wolk, 2012), and
reduced thickness in these regions was associated with time to diagno-
sis of dementia (Dickerson et al., 2011). Additionally, studies that have
compared cognitively normal individuals who subsequently progress
to MCI or AD dementia to those who remain cognitively normal have
demonstrated between-group differences in baseline MRI volumes
(Smith et al., 2007) or atrophy measures (Pacheco et al., 2015) in a
subset of cortical regions, including parietal and temporal areas.
A number of cross-sectional studies have also examined cortical
thickness differences between cognitively normal individuals with
versus without biomarker proﬁles consistent with AD pathology, as
determined by amyloid imaging or cerebrospinal ﬂuid (CSF). These
studies have demonstrated associations between biomarker positivity
and reduced mean cortical thickness of AD vulnerable regions
(Dickerson et al., 2009; Sabuncu et al., 2011) or similar cortical regions
(e.g., Becker et al., 2011; Doré et al., 2013).
Although prior studies, taken together, suggest that reductions in
cortical thickness are predictive of time to progression from normal
cognition to symptom onset of MCI, this question has not been directly
examined previously, to our knowledge. The present study was
designed to address this gap. Utilizing MRI data from the BIOCARD
study, whose participants were cognitively normal when ﬁrst enrolled,
we examinedwhethermean cortical thickness of AD vulnerable regions
is associated with time to onset of clinical symptoms of MCI.
The long follow-up of the cohort (mean = 11.8 years, max =
18.2 years), the substantial size (N = 240), and the availability of CSF
measures in the same individuals allowed us to extend prior work in a
number of ways. First, we examined the timing of cortical thinning in
AD vulnerable regions relative to the onset of symptoms of MCI. To do
so, we tested whether cortical thickness is similarly predictive of the
risk of clinical symptom onset for progression within a relatively short
time frame (less than 7 years from baseline) versus progression at a
later point in time, i.e., more than 7 years from baseline. This analysis
wasmotivated by current AD biomarkermodels that hypothesize struc-
tural MRI measures of brain atrophy become abnormal more proximal
to clinical symptom onset than measures of amyloid accumulation,
which are thought to become abnormal earlier during the preclinical
phase of AD (Jack et al., 2013). Second, we examined whether cortical
thickness of AD vulnerable regions was associated with CSF biomarkers
of neuronal injury (i.e., tau, phosphorylated tau) or a CSF biomarker of
β-amyloid. Lastly, previous studies on this general topic have tended
to include individuals in their 70′s, so it remains unclear whether AD-
related cortical thickness changes during preclinical AD can be
identiﬁed at younger ages. The present study was able to address this
issue since it included a large cohort of individuals who were primarily
middle-aged at their baseline MRI scan (mean (M) age = 56 years).
2. Method
2.1. Study design and participant selection
The study from which these data were drawn is known as the
BIOCARD study, which was designed to recruit and follow a cohort of
cognitively normal individuals who were primarily in middle age at
baseline. By design, approximately 75% of the participants had a ﬁrst
degree relative with dementia of the Alzheimer type. The overarching
goal was to identify variables among cognitively normal individuals
that could predict the subsequent development of mild to moderate
symptoms of AD. Recruitment procedures, baseline evaluations, and
annual clinical and cognitive assessments have been described in detail
elsewhere (Albert et al., 2014). Brieﬂy, the study was initiated at the
National Institutes of Health (NIH) in 1995, with recruitment conducted
by the staff of the Geriatric Psychiatry Branch of the intramural program
of theNational Institute ofMental Health, beginning in 1995 and ending
in 2005. After providing written informed consent, a total of 349individuals were enrolled in the study. Participants were administered
a comprehensive neuropsychological battery and clinical examination
annually, and MRI scans, CSF, and blood specimens were obtained
approximately every two years. In 2005, the study was stopped for
administrative reasons, and in 2009, a research team at the Johns
Hopkins School of Medicine was funded to re-establish the cohort,
continue the annual clinical and cognitive assessments and evaluate
the previously acquired MRI scans, CSF, and blood specimens. In 2015,
the collection of both MRI and CSF biomarkers was reinitiated, and
amyloid imaging was begun.
2.2. Clinical assessments and consensus diagnoses
Since the study has been conducted at Johns Hopkins, annual clinical
assessments have included the following: a physical and neurologic ex-
amination, record of medication use, behavioral and mood assessments
(Cummings et al., 1994; Yesavage et al., 1982), family history of demen-
tia, history of symptom onset, and a Clinical Dementia Rating (CDR)
based on a semi-structured interview (Hughes et al., 1982; Morris,
1993). Clinical assessments given at the NIH covered similar domains.
Annual cognitive assessments consist of a neuropsychological battery
covering all major cognitive domains (for comprehensive details, see
Albert et al., 2014).
The consensus diagnosis procedures implemented by the Johns
Hopkins team have been comparable with those used in the National
Institute on Aging Alzheimer's Disease Centers program: (1) clinical
data pertaining to the medical, neurologic, and psychiatric status of
the participant were examined; (2) reports of changes in cognition by
the participant and collateral sources were reviewed; and (3) decline
in cognitive performance, based on review of longitudinal testing from
multiple domains, was established. These three sources of data were
used to determine whether a participant was impaired. If a participant
was impaired, the likely etiology of the impairment was identiﬁed.
Then, the age at which the clinical symptoms began was estimated,
based primarily on the reports of the participant and collateral source
derived from the CDR. This same diagnostic process was retrospectively
applied to participants who had become cognitively impaired while the
study was being conducted at the NIH.
2.3. MRI assessments, image processing and regions of interest
The baseline MRI scans included in the present study were acquired
at the NIH. Scans were obtained using a standard multimodal protocol
using a GE 1.5T scanner. The scanning protocol included localizer
scans, axial Fast Spin Echo sequence (repetition time (TR) = 4250,
echo time (TE) = 108, ﬁeld of view (FOV) = 512 × 512, thickness/gap
=5.0/0.0 mm, ﬂip angle = 90, 28 slices), axial Flair sequence (TR =
9002, TE = 157.5, FOV = 256 × 256, thickness/gap = 5.0/0.0 mm, ﬂip
angle = 90, 28 slices), coronal Spoiled Gradient Echo (SPGR) sequence
(TR = 24, TE = 2, FOV = 256 × 256, thickness/gap = 2.0/0.0 mm, ﬂip
angle = 20, 124 slices), sagittal SPGR sequence (TR = 24, TE = 3,
FOV = 256 × 256, thickness/gap 1.5/0.0 mm, ﬂip angle = 45, 124
slices).
Cortical reconstruction and estimation of cortical thickness was
performed on the coronal SPGR scans using FreeSurfer (version 5.1),
an automated image processing pipeline that is documented and freely
available online (http://surfer.nmr.mgh.harvard.edu/). The technical
details of these methods have been described in prior publications
(e.g., Dale et al., 1999; Fischl and Dale, 2000; Fischl et al., 1999a,
1999b, 2004b). Brieﬂy, processing includes removal of non-brain tissue
(Segonne et al., 2004), segmentation of the subcorticalwhitematter and
deep gray matter structures (Fischl et al., 2002, 2004a), tessellation of
the gray matter-white matter boundary, and surface deformation
following intensity gradients to optimally place the gray/white and
gray/cerebrospinal ﬂuid borders (Dale et al., 1999; Dale and Sereno,
1993; Fischl and Dale, 2000). Parcellation of the cerebral cortex into
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al., 2004b) allows for representations of cortical thickness, calculated as
the closest distance from the gray/white boundary to the gray/CSF
boundary at each vertex (Fischl and Dale, 2000). The procedures for
the measurement of cortical thickness have been validated against
histological analysis (Rosas et al., 2002) and manual measurements
(Kuperberg et al., 2003; Salat et al., 2004), and FreeSurfermorphometric
procedures have been demonstrated to show good reliability and valid-
ity (Desikan et al., 2006; Han et al., 2006).
Following completion of the automated FreeSurfer pipeline, all scans
were reviewed to assess the quality of skull stripping and ensure that
cortical surfaces followed the gray and white matter boundaries.
Where needed, manual edits were performed to improve segmentation
and parcellation accuracy, which primarily included the correction of
pial surface misplacement (e.g., the inclusion of non-brain tissue) and
errors in white matter segmentation. This editing procedure was
conducted by operators blinded to the diagnostic status of the subjects
on follow-up.
The present study examined cortical thickness measures in eight
FreeSurfer-labeled regions of interest that were classiﬁed as ‘AD vulner-
able’ cortical regions by at least two previous studies' (i.e., cross-study
overlap includes Dickerson et al., 2009; Sabuncu et al., 2011; Wang et
al., 2015). These regions included the entorhinal cortex, temporal pole,
inferior temporal gyrus, middle temporal gyrus, inferior parietal cortex,
superior parietal cortex, precuneus, and posterior cingulate cortex
(averaged over the left and right hemispheres) (see Fig. 1). Note that
we did not adjust the thickness measures for intracranial cavity size,
as per standard procedure when evaluating cortical thickness (e.g.,
Westman et al., 2013). For each participant, the eight cortical thickness
measures were averaged to create a measure of mean thickness of AD
vulnerable regions, which served as the primary dependent variable in
the below analyses.
2.4. MRI scans used in the analyses
Baseline MRI scans were obtained from 331 participants in the
study; of these, 62 scans were excluded, either because coronal SPGRs
were not available (n = 22) or FreeSurfer surface reconstructions
were deemed unreliable (e.g., motion artifact or low contrast resultedFig. 1.Map of the eight of AD vulnerable regions based on FreeSurfer cortical labels, shown on
(bottom) views.in poor scan quality or regions were missing from surfaces, n = 40).
Of the 269 with useable FreeSurfer data, data from an additional 29
were not considered for analysis for reasons unrelated to scan quality
(n = 22 have not yet re-enrolled or withdrawn from the study and
n = 7 had clinical symptom onset at or prior to baseline, based on the
estimated age of onset established during the consensus diagnosis pro-
cedure). The analyses reported below therefore include 240 participants
who were cognitively normal at their baseline MRI scan (M duration of
follow-up = 11.8 years, SD= 3.7).
2.5. Cerebrospinal ﬂuid assessments
CSF measures were available for 170 of the participants who
underwent lumbar puncture within 6 months of their baseline MRI
scan (M gap time = 5.2 days between CSF draw and MRI, SD= 19.6).
CSF specimens were analyzed using the same protocol employed in
the Alzheimer's Disease Neuroimaging Initiative. As reported in
Moghekar et al. (2013), this protocol used the xMAP-based AlzBio3 kit
(Innogenetics, Ghent, Belgium) run on the Bioplex 200 system. The kit
contains monoclonal antibodies speciﬁc for Aβ1–42 (4D7A3), total tau
(t-tau) (AT120), and phosphorylated tau181p (p-tau) (AT270), each
chemically bonded to unique sets of color-coded beads, and analyte-
speciﬁc detector antibodies (HT7 and 3D6). Calibration curves were
produced for each biomarker using aqueous buffered solutions that
contained the combination of 3 biomarkers at concentrations ranging
from 25 to 1555 pg/mL for recombinant tau, 54–1799 pg/mL for syn-
thetic Aβ1–42 peptide, and 15–258 pg/mL for a tau synthetic peptide
phosphorylated at the threonine 181 position (i.e., the p-tau181p
standard). Each participant had all samples (run in triplicate) analyzed
on the same plate. See Moghekar et al. (2012) for additional details
regarding these procedures. The CSF specimen analyses were blinded
to subject diagnostic status on follow-up.
2.6. Statistical analyses
Group differences in descriptive statistics were compared with t-
tests for continuous variables or chi-square tests for dichotomous vari-
ables.We used Cox regressionmodels (i.e., proportional hazardmodels)
to determinewhethermeanbaseline cortical thickness of ADvulnerablethe pial surface of the left (left) and right (right) hemispheres for lateral (top) and medial
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To examine the issue of timing more carefully, we also examined
whether cortical thickness was associated with clinical symptom
onset for transitions occurring closer in time to baseline (i.e., transitions
more proximal to the MRI scan) relative to transitions further in time
frombaseline. To test this, we ran an additional Coxmodel that included
an indicator term for time (within 7 years) as part of the coefﬁcient for
cortical thickness. This is equivalent to treating thickness as a composi-
tion of two time-dependent variables, one only having an effect on risk
of progression within 7 years, the other after 7 years (Fisher and Lin,
1999), with coefﬁcients estimated using these corresponding methods.
Thus, for each individual, this model allowed the coefﬁcient for cortical
thickness on risk of progression to be time-dependent and different
within and after 7 years frombaseline, therefore allowing us to examine
the association between cortical thickness and risk of clinical symptom
onset for progressionwithin 7 years of baseline versus after 7 years from
baseline. Seven years was selected as the cut-point since this is the
mean time to clinical symptom onset in the data presented here (see
Section 3.1). All Cox regression models included data from two groups:
(1) participants who were cognitively normal at baseline and at their
last visit (n = 190) and (2) participants were cognitively normal
at baseline, but who received a diagnosis of MCI or dementia due
to AD at their last visit (n = 50). All measures were standardized (i.e.,
z-scored) before model ﬁtting and models were adjusted for age at
scan and gender. These Cox regression models were also re-run with
apolipoprotein E (APOE) genotype included as an additional dichoto-
mous covariate, given that APOE-4 genetic status is a genetic risk factor
for sporadic AD (Farrer et al., 1997). In these analyses, APOE-4 carriers
were coded as 1, whereas non-carriers were coded as 0 (n=8 individ-
uals with one APOE-2 and one APOE-4 allele were excluded).
We calculated the hazard ratio (HR; i.e., relative hazard) for each
thickness measure, which indicates the change in relative risk of
progression for each one unit change in the predictor. A HR of 0.51, for
example, means the hazard of clinical symptom onset is reduced by a
factor of 0.51 (i.e., by 49%) for each standard deviation increase in
cortical thickness. In contrast, a HR of 1.70 means the hazard of clinical
symptom onset is increased by a factor of 1.70 (i.e., by 70%) for each
standard deviation increase in cortical thickness.
Linear regression models were used to examine the association
between AD vulnerable regions and CSF measures acquired within
6 months of an individual's scan date. Separate models were run for
Aβ1–42, tau, and p-tau. For eachmodel, the CSFmeasure, age, and gender
served as predictors of mean thickness of the AD vulnerable regions. All
analyses were run in R, version 3.2.2.Table 1
Baseline participant characteristics for the entire BIOCARD cohort and participants in the analy
Values reﬂect means (standard deviations) unless otherwise indicated.
Entire BIOCARD cohort
N 349
Age, years 57.3 (10.4)
Gender, females (%) 57.6%
Ethnicity, Caucasian (%) 97.1%
ApoE-4 carriers (%) 33.6%
Education, years 17.0 (2.4)
MMSE score 29.5 (0.9)
Thickness of AD vulnerable regions, mm –
CSF Aβ1–42, pg/ml –
CSF t-tau, pg/ml –
CSF p-tau, pg/ml –
⁎ Signiﬁcant difference between individuals who have remained cognitively normal vs. prog3. Results
Table 1 shows the comparison of the subjects who remained normal
over time (n = 190) compared to those who progressed to MCI on
follow-up (n=50). At baseline, individuals who have since progressed
to clinical symptoms of MCI were signiﬁcantly older than those who
have remained normal. Table 1 also includes baseline demographic
characteristics for the entire BIOCARD cohort, for purposes of compari-
son. Of note, individuals with a diagnosis of ‘Impaired not MCI’ were
included in the group of cognitively normal subjects; results were com-
parable when these subjects were excluded. Results for the associations
between cortical thickness of AD vulnerable regions and time to clinical
symptom onset were comparable when APOE-4 genetic status was
included as an additional dichotomous covariate (data not shown).
See the Supplementary Materials section for additional information
about the characteristics of the subjects in the analyses.
3.1. Relationship between mean cortical thickness of AD vulnerable regions
and time to onset of clinical symptoms
Mean baseline cortical thickness of AD vulnerable regions did not
differ between individuals who remained cognitively normal compared
to those who subsequently received a diagnosis of MCI or dementia due
to AD (p = 0.12). The mean time from baseline to clinical symptom
onset was 7.1 years (SD = 3.5; range 0.7–14.4). In the Cox regression
model, therewas no association betweenmean cortical thickness across
all AD vulnerable regions and time to clinical symptom onset, when the
length of time between the baseline scan and clinical symptom onset
was not considered, HR = 0.77, p= 0.11, 95% CI [0.57, 1.06].
Next, we examined whether cortical thickness was associated with
clinical symptom onset for progression more proximal to baseline (i.e.,
within 7 years) versus after 7 years from baseline. The mean time
from baseline to clinical symptom onset for individuals who progressed
within 7 years of their baseline scan was 3.9 years (SD= 2.2, range =
0.7–6.9; n = 22), versus 9.6 years (SD = 2.0, range = 7.1–14.4; n =
28) for those who progressed N7 years from their baseline scan. With
progression modeled differently within versus after 7 years from base-
line (see Section 2.6 for model details), mean cortical thickness of AD
vulnerable regions was signiﬁcantly associated with clinical symptom
onset within 7 years of baseline, but not after 7 years. Speciﬁcally,
each standard deviation increase inmean thickness of AD vulnerable re-
gions was associated with a reduced relative risk of clinical symptom
onset for progression at time points within 7 years of the baseline
scan, HR = 0.50, p = 0.03, 95% CI [0.28, 0.92], but not N7 years fromses; characteristics for participants in the analyses are also stratiﬁed by clinical outcome.
Participants in analyses
All in analyses Remained normal Progressed to MCI or AD
240 190 50
56.0 (9.8) 54.4 (8.8) 62.2 (11.2)⁎
61.7% 64.7% 50.0%
97.9% 99.5% 92.0%
29.2% 32.1% 36.0%
17.0 (2.4) 17.1 (2.3) 16.7 (2.6)
29.6 (0.8) 29.7 (0.7) 29.3 (1.0)⁎
2.77 (0.13) 2.78 (0.12) 2.74 (0.15)
406.2 (98.0)
[n= 170]
414.0 (92.4)
[n= 137]
373.6 (114.5)
[n= 33]
69.0 (28.0)
[n= 170]
67.2 (27.4)
[n= 137]
76.4 (29.6)
[n= 33]
36.6 (15.6)
[n= 170]
35.1 (11.2)
[n= 137]
42.6 (22.4)
[n= 33]
ressed to MCI or AD dementia, p b 0.05.
Fig. 2. Scatterplot showing the partial correlation between mean thickness of AD
vulnerable regions and standardized CSF p-tau levels (adjusted for age and gender).
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the individual regions of interest are shown in Table 2 for reference.
3.2. Relationship between mean cortical thickness of AD vulnerable regions
and CSF
Mean baseline CSF biomarker levels are shown in Table 1. Linear re-
gression analyses revealed a signiﬁcant negative association between
the mean thickness of AD vulnerable regions and CSF p-tau (Fig. 2),
such that individuals with smaller mean cortical thickness demonstrat-
ed higher levels of p-tau, β=−0.20, p = 0.006. In contrast, the mean
thickness of AD vulnerable regions was not associated with CSF Aβ1–42
(β= 0.01, p = 0.90) or t-tau (β=−0.05, p = 0.51). See the Supple-
mentary Materials section for auxiliary analyses of the CSF data, using
Cox regression models comparable to those described above.
4. Discussion
In the present study, we examined the association between mean
cortical thickness across eight ‘AD vulnerable’ regions and time to
onset of clinical symptoms in a cohort of well-characterized, longitudi-
nally followed individuals who were cognitively normal at baseline, a
subset of whom subsequently developed MCI or dementia due to AD
(n = 50). We also examined whether mean thickness in these regions
was related to cerebrospinal ﬂuid biomarkers of AD pathology, includ-
ing biomarkers of neuronal injury (tau and p-tau) and β-amyloid.
Mean cortical thickness of the AD vulnerable regions was signiﬁcantly
associated with time to onset of clinical symptoms for progression
within 7 years of baseline, but not for progression more than 7 years
from baseline. This temporally dependent effect was evident when
time to onset was modeled differently for progression within versus
after 7 years from baseline, which corresponds to themean time to clin-
ical symptom onset across the 50 individuals who progressed to MCI or
dementia over time. We also found that mean cortical thickness of AD
vulnerable regions was inversely associated with levels of CSF p-tau,
but not CSF total tau or Abeta.
These ﬁndings extend prior research in a number of ways. First, the
cohort's extensive longitudinal follow-up allowed us to examine the
timing of cortical thickness changes during preclinical AD, with results
suggesting that these changes are more likely to be evident in the
years proximal to clinical symptom onset. These results therefore
extend previous work that used time to diagnosis of dementia as the
outcome (Dickerson et al., 2011). Second, we deﬁned AD vulnerable
regions by examining cortical areas that had been identiﬁed as altered
during AD by several different groups of investigators (Dickerson et
al., 2009; Sabuncu et al., 2011; Wang et al., 2015), suggesting these
regions are sensitive to AD-related changes across multiple cohorts.
Third, the BIOCARD cohort was primarily middle aged at baseline. ThisTable 2
Hazard ratios [95% conﬁdence intervals] and p-values for cortical thickness of AD vulner-
able regions in relation to clinical symptom onset, stratiﬁed by progressionwithin vs. after
7 years from baseline.
≤7 years from baseline N7 years from baseline
HR p-value HR p-value
Average of AD vulnerable
regions
0.50 [0.28, 0.92] 0.03 1.08 [0.74, 1.57] 0.70
Entorhinal cortex 0.79 [0.52, 1.19] 0.26 0.92 [0.63, 1.34] 0.65
Temporal pole 0.61 [0.37, 1.02] 0.058 0.82 [0.51, 1.31] 0.41
Inferior temporal gyrus 0.48 [0.28, 0.81] 0.006 1.30 [0.91, 1.87] 0.16
Middle temporal gyrus 0.42 [0.22, 0.80] 0.008 1.07 [0.72, 1.58] 0.75
Inferior parietal cortex 0.71 [0.43, 1.16] 0.17 1.40 [1.00, 1.96] 0.05
Superior parietal cortex 0.73 [0.48, 1.11] 0.14 1.10 [0.77, 1.59] 0.60
Precuneus 0.58 [0.34, 0.98] 0.04 1.16 [0.81, 1.66] 0.42
Posterior cingulate cortex 0.87 [0.55, 1.37] 0.55 1.15 [0.75, 1.78] 0.52allowed us to examine cortical thickness measures in a younger group
than has been done previously. Moreover, we used an earlier diagnostic
time point (i.e., time to clinical symptom onset), which is generally
earlier than the date of diagnosis of MCI.
These MRI results are in line with studies ﬁnding that individuals
who progress from normal cognition to MCI or dementia due to AD
demonstrate greater atrophy in cortical regions outside the MTL,
relative to those who remain normal, in both sporadic (Pacheco et al.,
2015; Smith et al., 2007) and familial AD (Fox et al., 2001). To our
knowledge, only one prior study has examined the mean thickness of
AD vulnerable regions in cognitively normal individuals in relation to
time to a clinical outcome. Dickerson et al. (2011) found a signiﬁcant as-
sociation between cortical thickness and time to diagnosis of dementia
among 15 individuals whowere diagnosedwith dementia due to AD an
average of 8 years later. Although theseﬁndings suggestwe should have
found a signiﬁcant association between theMRI thicknessmeasures and
time to symptom onset for those individuals who transitioned to MCI
after 7 years, it's difﬁcult to compare our results with those of Dickerson
et al. because they did not provide information about the onset of symp-
toms of MCI relative to the timing of the MRI scan (i.e., the outcome in
the present study).
It is noteworthy thatwe previously reported that baseline entorhinal
cortex thickness and hippocampal volume (particularly in the right
hemisphere) were signiﬁcantly associated with time to onset of clinical
symptoms for the cohort taken as a whole (i.e., the Cox regression
models in these prior analyses did not include a 7-year indicator)
(Soldan et al., 2015). Although the results in the present study were in
the expected direction, entorhinal cortex thickness derived from
FreeSurfer was not signiﬁcantly associated with time to onset of clinical
symptoms within or after 7 years. This discrepancy between our prior
and current results may be due to differences in themethod of entorhi-
nal cortex assessment. The entorhinal cortex is challenging to measure
(Feczko et al., 2009) and semi-automated methods such as LDDMM
may be better at detecting subtle changes in a region that is affected
by multiple anatomical factors, including small size, collateral sulcus
variability, and the presence of dura adjacent to the pial surface
(Feczko et al., 2009). Taken together, our prior ﬁndings and the current
ones suggest that MTL regions atrophy ﬁrst, with atrophy in other AD
vulnerable cortical regions occurring later in the progression of preclin-
ical AD. These ﬁndings may have implications for the use of MRI
biomarkers in clinical trials among cognitively normal individuals at
risk for AD. Additionally, this interpretation is consistent with
neuropathological studies showing that neuroﬁbrillary tangles initially
121C. Pettigrew et al. / NeuroImage: Clinical 12 (2016) 116–122accumulate in MTL regions before spreading to other regions, including
adjacent temporal and parietal areas (Braak and Braak, 1991).
It is also noteworthy that mean cortical thickness of AD vulnerable
regions, hypothesized to be a marker of neuronal injury, was associated
with levels of CSF phosphorylated tau, but not CSF Abeta. Wang et al.
(2015) found an association between mean cortical thickness of AD
vulnerable regions and CSF total tau, but not Abeta (cf. Sabuncu et al.,
2011), in cognitively normal individuals whowere tau positive (though
their study did not include measures of p-tau). Unlike Wang et al.
(2015), we did not ﬁnd a relationship between cortical thickness and
total tau in the present study, though this may be due in part to partic-
ipant characteristics. Participants in the study by Wang et al. were in
their early 70′s and, as there are age-related changes in tau, may have
harbored more tau pathology than the primarily middle-aged partici-
pants included here. Additionally, subtle differences in CSF assays across
sites could underlie the reason we found a relationship with p-tau but
not tau. In future analyses, it will be important to assess the rate of
change in AD vulnerable regions in relation to clinical symptom onset,
aswell as in relation to the rate of change in other biomarkers including
CSF tau and p-tau.
These ﬁndings, taken as awhole, are in agreementwith hypothetical
models of preclinical AD that suggest structural MRI abnormalities
occur more proximal to symptom onset than do changes in measures
of amyloid and tau accumulation (Jack et al., 2013; Sperling et al.,
2011). In line with this, we previously demonstrated that other AD bio-
markers, including baseline cerebrospinal ﬂuid (Moghekar et al., 2013)
and medial temporal lobe volumetric MRI measures (Soldan et al.,
2015) in this same cohort, were signiﬁcantly associated with time to
onset of clinical symptoms of MCI. In these prior studies, the mean
time from biomarker assessment to symptom onset ranged from 5 to
6 years. Importantly, these prior analyses did not include a cut-point
indicator in the Cox regression models, such as that used here. This
suggests that CSF and medial temporal lobe MRI volumetric measures
may be predictive of progression over a longer time frame than
measures of cortical thickness.
This study must be interpreted within the context of its limitations.
First, the BIOCARD cohort is a convenience sample and consists of
well-educated, primarily Caucasian participants, the majority of whom
have a family history of AD. These factors may limit generalization to
the population at large. Second, although the brain regions examined
here were selected on the basis of prior publications by other groups,
we used cortical parcellations derived from FreeSurfer, which may be
larger in size than the regions identiﬁed by some previous studies, and
thus not directly comparable. Lastly, it is important to note that in
these analyses, the cut-point for the indicator variable was selected on
the basis of the mean time from baseline to clinical symptom onset for
the speciﬁc measure under evaluation. We are currently applying
change point models to a broad set of data which incorporates each
domain of assessment obtained in this cohort (e.g., MRI, CSF, cognitive
test scores) in order to examine the timing of changes in thesemeasures
in relation to one another and in relation to symptom onset during
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